Cancer Fighters Thrive

SUMMER 2012

Cancer Fighters Thrive is a quarterly print and online magazine bringing readers practical, innovative and inspirational information about cancer treatment and survivorship.

Issue link: http://cancerfightersthrive.epubxp.com/i/61344

Contents of this Issue

Navigation

Page 16 of 47

CANCER TYPE Q & A HAVE THERE BEEN ANY RECENT ADVANCES IN THE TREATMENT OF NEUROLOGICAL CANCERS THAT ARE ESPECIALLY EXCITING? There are several exciting vaccine therapies on the horizon for the treatment of primary brain tumors. The most recently approved therapy is Avastin® (bevacizumab). This approval was exciting because it was the first therapy approved by the US Food and Drug Administration for brain tumors in a number of years. It works by blocking the growth of new blood vessels (anti-angiogenesis). The fundamental treatment for brain tumors centers on surgical resection, radiation, chemotherapy, and immunotherapy. The ongoing work on vaccine therapy holds much promise for the future. When faced with fighting any cancer, but particularly a neurological cancer, the experience of the members of the care team is very important. — Clinton J. Baird, MD Code CFT12 * These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Articles in this issue

Links on this page

Archives of this issue

view archives of Cancer Fighters Thrive - SUMMER 2012